Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Analysis Of The Vaccine-Induced Influenza B Virus Hemagglutinin-Specific Antibody Dependent Cellular Cytotoxicity Response.

de Vries RD, Nieuwkoop NJ, Krammer F, Hu B, Rimmelzwaan GF.

Virus Res. 2019 Dec 11:197839. doi: 10.1016/j.virusres.2019.197839. [Epub ahead of print]

PMID:
31837382
2.

Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.

Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, Siljander H, Rewers M, Choy DF, Wilson MS, Larman HB, Nelson AN, Griffin DE, de Swart RL, Elledge SJ.

Science. 2019 Nov 1;366(6465):599-606. doi: 10.1126/science.aay6485.

PMID:
31672891
3.

Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles.

Petrova VN, Sawatsky B, Han AX, Laksono BM, Walz L, Parker E, Pieper K, Anderson CA, de Vries RD, Lanzavecchia A, Kellam P, von Messling V, de Swart RL, Russell CA.

Sci Immunol. 2019 Nov 1;4(41). pii: eaay6125. doi: 10.1126/sciimmunol.aay6125.

PMID:
31672862
4.

Modeling the measles paradox reveals the importance of cellular immunity in regulating viral clearance.

Morris SE, Yates AJ, de Swart RL, de Vries RD, Mina MJ, Nelson AN, Lin WW, Kouyos RD, Griffin DE, Grenfell BT.

PLoS Pathog. 2018 Dec 28;14(12):e1007493. doi: 10.1371/journal.ppat.1007493. eCollection 2018 Dec.

5.

Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands.

Laksono BM, de Vries RD, Verburgh RJ, Visser EG, de Jong A, Fraaij PLA, Ruijs WLM, Nieuwenhuijse DF, van den Ham HJ, Koopmans MPG, van Zelm MC, Osterhaus ADME, de Swart RL.

Nat Commun. 2018 Nov 23;9(1):4944. doi: 10.1038/s41467-018-07515-0.

6.

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.

de Vries RD, Herfst S, Richard M.

Vaccines (Basel). 2018 Jul 25;6(3). pii: E46. doi: 10.3390/vaccines6030046. Review.

7.

Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

de Vries RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, van Trierum SE, Pronk MR, Lamers MM, Richard M, Nieuwenhuijse DF, Koopmans MPG, Kreijtz JHCM, Fouchier RAM, Osterhaus ADME, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2018 Jul 13;218(4):614-623. doi: 10.1093/infdis/jiy214.

8.

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.

Altenburg AF, van Trierum SE, de Bruin E, de Meulder D, van de Sandt CE, van der Klis FRM, Fouchier RAM, Koopmans MPG, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2018 Apr 24;8(1):6474. doi: 10.1038/s41598-018-24820-2.

9.

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.

Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, Stertman L.

Immunol Res. 2018 Apr;66(2):224-233. doi: 10.1007/s12026-018-8991-x.

10.

Paramyxovirus Infections in Ex Vivo Lung Slice Cultures of Different Host Species.

De Vries RD, Rennick LJ, Duprex WP, De Swart RL.

Methods Protoc. 2018 Mar 27;1(2). pii: E12. doi: 10.3390/mps1020012.

11.

In Vitro Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells.

Laksono BM, Grosserichter-Wagener C, de Vries RD, Langeveld SAG, Brem MD, van Dongen JJM, Katsikis PD, Koopmans MPG, van Zelm MC, de Swart RL.

J Virol. 2018 Mar 28;92(8). pii: e00131-18. doi: 10.1128/JVI.00131-18. Print 2018 Apr 15.

12.

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

de Vries RD, Nieuwkoop NJ, van der Klis FRM, Koopmans MPG, Krammer F, Rimmelzwaan GF.

J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546.

13.

Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.

de Swart RL, de Vries RD, Rennick LJ, van Amerongen G, McQuaid S, Verburgh RJ, Yüksel S, de Jong A, Lemon K, Nguyen DT, Ludlow M, Osterhaus ADME, Duprex WP.

NPJ Vaccines. 2017 Aug 1;2:22. doi: 10.1038/s41541-017-0022-8. eCollection 2017.

14.

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM, van Amerongen G, Volz A, Hendriks RW, de Swart RL, Sutter G, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2017 Aug 17;7(1):8580. doi: 10.1038/s41598-017-08719-y.

15.

Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Altenburg AF, Magnusson SE, Bosman F, Stertman L, de Vries RD, Rimmelzwaan GF.

Clin Exp Immunol. 2017 Oct;190(1):19-28. doi: 10.1111/cei.13004. Epub 2017 Jul 24.

16.

Human CD8+ T Cells Damage Noninfected Epithelial Cells during Influenza Virus Infection In Vitro.

van de Sandt CE, Bárcena M, Koster AJ, Kasper J, Kirkpatrick CJ, Scott DP, de Vries RD, Herold S, Rimmelzwaan GF, Kuiken T, Short KR.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):536-546. doi: 10.1165/rcmb.2016-0377OC.

PMID:
28613916
17.

Delineating morbillivirus entry, dissemination and airborne transmission by studying in vivo competition of multicolor canine distemper viruses in ferrets.

de Vries RD, Ludlow M, de Jong A, Rennick LJ, Verburgh RJ, van Amerongen G, van Riel D, van Run PRWA, Herfst S, Kuiken T, Fouchier RAM, Osterhaus ADME, de Swart RL, Duprex WP.

PLoS Pathog. 2017 May 8;13(5):e1006371. doi: 10.1371/journal.ppat.1006371. eCollection 2017 May.

18.

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, van Binnendijk RS, Krammer F, Koopmans MPG, Rimmelzwaan GF.

Vaccine. 2017 Jan 5;35(2):238-247. doi: 10.1016/j.vaccine.2016.11.082. Epub 2016 Nov 30.

PMID:
27914742
19.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

20.

Measles Virus Host Invasion and Pathogenesis.

Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL.

Viruses. 2016 Jul 28;8(8). pii: E210. doi: 10.3390/v8080210. Review.

21.

Viral vector-based influenza vaccines.

de Vries RD, Rimmelzwaan GF.

Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901. Epub 2016 Jul 25. Review.

22.

Universal influenza vaccines: a realistic option?

de Vries RD, Altenburg AF, Rimmelzwaan GF.

Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S120-S124. doi: 10.1016/j.cmi.2015.12.005. Epub 2016 Apr 26.

23.

Influenza B viruses: not to be discounted.

van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD.

Future Microbiol. 2015;10(9):1447-65. doi: 10.2217/fmb.15.65. Epub 2015 Sep 11. Review.

PMID:
26357957
24.

Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.

Wiersma LC, Rimmelzwaan GF, de Vries RD.

Vaccines (Basel). 2015 Mar 26;3(2):239-62. doi: 10.3390/vaccines3020239. Review.

25.

Universal influenza vaccines, science fiction or soon reality?

de Vries RD, Altenburg AF, Rimmelzwaan GF.

Expert Rev Vaccines. 2015;14(10):1299-301. doi: 10.1586/14760584.2015.1060860. Epub 2015 Jun 23.

PMID:
26104835
26.

Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine.

de Vries RD, De Gruyter HL, Bestebroer TM, Pronk M, Fouchier RA, Osterhaus AD, Sutter G, Kreijtz JH, Rimmelzwaan GF.

Emerg Infect Dis. 2015 Jun;21(6):1086-8. doi: 10.3201/eid2106.150021. No abstract available.

27.

Morbillivirus infections: an introduction.

de Vries RD, Duprex WP, de Swart RL.

Viruses. 2015 Feb 12;7(2):699-706. doi: 10.3390/v7020699. Review.

28.

Measles immune suppression: functional impairment or numbers game?

de Vries RD, de Swart RL.

PLoS Pathog. 2014 Dec 18;10(12):e1004482. doi: 10.1371/journal.ppat.1004482. eCollection 2014 Dec. No abstract available.

29.

Virus-specific T cells as correlate of (cross-)protective immunity against influenza.

Altenburg AF, Rimmelzwaan GF, de Vries RD.

Vaccine. 2015 Jan 15;33(4):500-6. doi: 10.1016/j.vaccine.2014.11.054. Epub 2014 Dec 9. Review.

PMID:
25498210
30.

Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.

Rennick LJ, de Vries RD, Carsillo TJ, Lemon K, van Amerongen G, Ludlow M, Nguyen DT, Yüksel S, Verburgh RJ, Haddock P, McQuaid S, Duprex WP, de Swart RL.

J Virol. 2015 Feb;89(4):2192-200. doi: 10.1128/JVI.02924-14. Epub 2014 Dec 3.

31.

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A.

Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735. Review.

32.

Measles vaccination of nonhuman primates provides partial protection against infection with canine distemper virus.

de Vries RD, Ludlow M, Verburgh RJ, van Amerongen G, Yüksel S, Nguyen DT, McQuaid S, Osterhaus AD, Duprex WP, de Swart RL.

J Virol. 2014 Apr;88(8):4423-33. doi: 10.1128/JVI.03676-13. Epub 2014 Feb 5.

33.

Complete Genome Sequence of Phocine Distemper Virus Isolated from a Harbor Seal (Phoca vitulina) during the 1988 North Sea Epidemic.

de Vries RD, Verburgh RJ, van de Bildt MW, Osterhaus AD, de Swart RL.

Genome Announc. 2013 Jun 27;1(3). pii: e00291-13. doi: 10.1128/genomeA.00291-13.

34.

Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus.

Ludlow M, de Vries RD, Lemon K, McQuaid S, Millar E, van Amerongen G, Yüksel S, Verburgh RJ, Osterhaus AD, de Swart RL, Duprex WP.

J Gen Virol. 2013 Sep;94(Pt 9):1933-44. doi: 10.1099/vir.0.054650-0. Epub 2013 Jun 19.

PMID:
23784446
35.

Paramyxovirus infections in ex vivo lung slice cultures of different host species.

Nguyen DT, de Vries RD, Ludlow M, van den Hoogen BG, Lemon K, van Amerongen G, Osterhaus AD, de Swart RL, Duprex WP.

J Virol Methods. 2013 Oct;193(1):159-65. doi: 10.1016/j.jviromet.2013.06.016. Epub 2013 Jun 15.

PMID:
23777750
36.

Measles virus infection of epithelial cells in the macaque upper respiratory tract is mediated by subepithelial immune cells.

Ludlow M, Lemon K, de Vries RD, McQuaid S, Millar EL, van Amerongen G, Yüksel S, Verburgh RJ, Osterhaus AD, de Swart RL, Duprex WP.

J Virol. 2013 Apr;87(7):4033-42. doi: 10.1128/JVI.03258-12. Epub 2013 Jan 30.

37.

A prominent role for DC-SIGN+ dendritic cells in initiation and dissemination of measles virus infection in non-human primates.

Mesman AW, de Vries RD, McQuaid S, Duprex WP, de Swart RL, Geijtenbeek TB.

PLoS One. 2012;7(12):e49573. doi: 10.1371/journal.pone.0049573. Epub 2012 Dec 5.

38.

Measles immune suppression: lessons from the macaque model.

de Vries RD, McQuaid S, van Amerongen G, Yüksel S, Verburgh RJ, Osterhaus AD, Duprex WP, de Swart RL.

PLoS Pathog. 2012;8(8):e1002885. doi: 10.1371/journal.ppat.1002885. Epub 2012 Aug 30.

39.

Evaluating measles vaccines: can we assess cellular immunity?

de Vries RD, de Swart RL.

Expert Rev Vaccines. 2012 Jul;11(7):779-82. doi: 10.1586/erv.12.45.

PMID:
22913254
40.

Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets.

Nguyen DT, Ludlow M, van Amerongen G, de Vries RD, Yüksel S, Verburgh RJ, Osterhaus AD, Duprex WP, de Swart RL.

Vaccine. 2012 Jul 20;30(34):5073-80. doi: 10.1016/j.vaccine.2012.05.079. Epub 2012 Jun 21.

PMID:
22705079
41.

Recombinant canine distemper virus strain Snyder Hill expressing green or red fluorescent proteins causes meningoencephalitis in the ferret.

Ludlow M, Nguyen DT, Silin D, Lyubomska O, de Vries RD, von Messling V, McQuaid S, De Swart RL, Duprex WP.

J Virol. 2012 Jul;86(14):7508-19. doi: 10.1128/JVI.06725-11. Epub 2012 May 2.

42.

The pathogenesis of measles.

de Vries RD, Mesman AW, Geijtenbeek TB, Duprex WP, de Swart RL.

Curr Opin Virol. 2012 Jun;2(3):248-55. doi: 10.1016/j.coviro.2012.03.005. Epub 2012 Apr 5. Review.

PMID:
22483507
43.

Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4⁺ T cells but are incapable of cross-presentation.

van der Vlist M, de Witte L, de Vries RD, Litjens M, de Jong MA, Fluitsma D, de Swart RL, Geijtenbeek TB.

Eur J Immunol. 2011 Sep;41(9):2619-31. doi: 10.1002/eji.201041305. Epub 2011 Aug 8.

44.

Early target cells of measles virus after aerosol infection of non-human primates.

Lemon K, de Vries RD, Mesman AW, McQuaid S, van Amerongen G, Yüksel S, Ludlow M, Rennick LJ, Kuiken T, Rima BK, Geijtenbeek TB, Osterhaus AD, Duprex WP, de Swart RL.

PLoS Pathog. 2011 Jan 27;7(1):e1001263. doi: 10.1371/journal.ppat.1001263.

45.

In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques.

de Vries RD, Lemon K, Ludlow M, McQuaid S, Yüksel S, van Amerongen G, Rennick LJ, Rima BK, Osterhaus AD, de Swart RL, Duprex WP.

J Virol. 2010 May;84(9):4714-24. doi: 10.1128/JVI.02633-09. Epub 2010 Feb 24.

46.

Specific CD8(+) T-lymphocytes control dissemination of measles virus.

de Vries RD, Yüksel S, Osterhaus AD, de Swart RL.

Eur J Immunol. 2010 Feb;40(2):388-95. doi: 10.1002/eji.200939949.

47.

Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis.

Duan R, de Vries RD, van Dun JM, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM.

J Infect Dis. 2009 Nov 1;200(9):1402-14. doi: 10.1086/606028.

PMID:
19795980
48.

Measles vaccination: new strategies and formulations.

de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL.

Expert Rev Vaccines. 2008 Oct;7(8):1215-23. doi: 10.1586/14760584.7.8.1215. Review.

PMID:
18844595
49.

Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis.

Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM.

J Infect Dis. 2008 Sep 1;198(5):659-63. doi: 10.1086/590668.

PMID:
18627246
50.

DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes.

de Witte L, de Vries RD, van der Vlist M, Yüksel S, Litjens M, de Swart RL, Geijtenbeek TB.

PLoS Pathog. 2008 Apr 18;4(4):e1000049. doi: 10.1371/journal.ppat.1000049.

Supplemental Content

Loading ...
Support Center